| abstract |
The present disclosure provides compositions comprising a plurality of inhibitors targeting translational factors involved in cap-dependent mRNA translation initiation, including inhibitors against eIF4A, eIF4E, MNK, or any combination thereof. The present disclosure also provides methods for the treatment of hyperproliferative disorders, such as cancer, with combination therapies of translation inhibitors. |